Mereo BioPharma (MREO) Net Income towards Common Stockholders (2023 - 2025)
Historic Net Income towards Common Stockholders for Mereo BioPharma (MREO) over the last 3 years, with Q3 2025 value amounting to -$7.0 million.
- Mereo BioPharma's Net Income towards Common Stockholders rose 5317.65% to -$7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$41.6 million, marking a year-over-year increase of 825.98%. This contributed to the annual value of -$43.3 million for FY2024, which is 4678.95% down from last year.
- Mereo BioPharma's Net Income towards Common Stockholders amounted to -$7.0 million in Q3 2025, which was up 5317.65% from -$14.6 million recorded in Q2 2025.
- Over the past 5 years, Mereo BioPharma's Net Income towards Common Stockholders peaked at -$1.8 million during Q2 2023, and registered a low of -$15.0 million during Q3 2024.
- Over the past 3 years, Mereo BioPharma's median Net Income towards Common Stockholders value was -$9.1 million (recorded in 2023), while the average stood at -$9.7 million.
- Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first plummeted by 59988.58% in 2024, then skyrocketed by 5317.65% in 2025.
- Quarter analysis of 3 years shows Mereo BioPharma's Net Income towards Common Stockholders stood at -$9.1 million in 2023, then increased by 22.65% to -$7.0 million in 2024, then grew by 0.31% to -$7.0 million in 2025.
- Its Net Income towards Common Stockholders stands at -$7.0 million for Q3 2025, versus -$14.6 million for Q2 2025 and -$12.9 million for Q1 2025.